1 2 3 4
In moderate to severe RA, Help patients get back to many of the activities they love
ACTIVE Movement ENABLE Explore Support ENBREL
ENBREL + MTX achieved significant improvements in physical function vs MTX alone as measured by HAQ-DI by Week 2 and out to Year 3.*
* In the TEMPO study, mean HAQ scores at baseline, week 2, and year 3 were 1.7, 1.5, and 1.1 in the MTX arm (n=228) and 1.8, 1.3, and 0.8 in the Enbrel + MTX arm (n=231), respectively. HAQ-DI = Health Assessment Questionnaire-Disability Index.
Review Clinical Data
For your patients with moderate to severe RA,
ENBREL offers significant results sustained over time.

An inside look at patient and professional perspectives on treating psoriatic arthritis
and moderately to severely active rheumatoid arthritis (RA).

Approach It Like A Pro
Watch the Documentary

Important Safety Considerations

The ENBREL Support™ card offers eligible patients*:

ENBREL Support™ Card Criteria:

*Eligibility Limits

* Eligibility Criteria: Open to patients with an ENBREL prescription and commercial insurance for ENBREL. Patients may not seek reimbursement for value received from the ENBREL Support™ card from any third-party payers, including a flexible spending account or health care savings account. This program is not open to uninsured patients or patients receiving prescription reimbursement under any federal, state, or government-funded health care program, such as Medicare, Medicare Advantage, Medicare Part D, Medicaid, Medigap, Veterans Affairs (VA), the Department of Defense (DoD), or TRICARE, or where prohibited by law. If at any time patients begin receiving prescription drug coverage under any such federal, state, or government-funded health care program, patients will no longer be able to use this card and you must call ENBREL Support™ at 1-888-4ENBREL (8 am to 8 pm ET, Monday-Friday) to stop participation. Restrictions may apply. Offer subject to change or discontinuation without notice. This is not health insurance.

Program Details: For all eligible patients, the ENBREL Support™ card program may offer:

  • First 6 months at no out-of-pocket cost to you
  • After 6 months, $10 or less out-of-pocket per month

Each time patients fill their ENBREL prescription, they will receive 50% off their out-of-pocket costs or pay no more than $10 per month—whichever helps them more.

Program provides up to $4,000 of assistance per patient for each 6-month period. Patient is responsible for costs above these amounts. Patients may use the card each time they fill their ENBREL prescription.

For patients with moderate to severe plaque psoriasis, who are first starting ENBREL and prescribed 50 mg twice-weekly dosing, program provides an additional $2,000 per patient for the first 3 months of therapy only.

Patients' participation in the program may be renewed every 12 months by visiting EnbrelSupport.com or calling 1-888-4ENBREL.


ENBREL is indicated for reducing signs and symptoms, inducing major clinical response, inhibiting the progression of structural damage, and improving physical function in patients with moderately to severely active rheumatoid arthritis. ENBREL can be initiated in combination with methotrexate (MTX) or used alone.

ENBREL is indicated for reducing signs and symptoms of moderately to severely active polyarticular juvenile idiopathic arthritis in patients ages 2 and older.

ENBREL is indicated for reducing signs and symptoms, inhibiting the progression of structural damage of active arthritis, and improving physical function in patients with psoriatic arthritis. ENBREL can be used in combination with methotrexate in patients who do not respond adequately to methotrexate alone.

ENBREL is indicated for reducing signs and symptoms in patients with active ankylosing spondylitis.

Supportive data
Moderate to Severe Rheumatoid Arthritis

In medical studies, ENBREL was shown to be clinically effective in about 2 out of 3 adults with moderate to severe RA at 3 months. ENBREL has been shown to begin working in as few as 2 weeks, and most patients who benefit will do so within 3 months. In another medical study, 55% of patients who were evaluated 5 years after beginning ENBREL therapy had no further progression of joint damage.

Psoriatic Arthritis

In a medical study, ENBREL was shown to be effective in about 50% of psoriatic arthritis patients at 6 months. Clinical responses were apparent at the time of the first visit (4 weeks) and were maintained through 6 months of therapy.

You are leaving Enbrel.com/RheumPro
Please know that Amgen does not endorse and are not responsible for the content included on the site you are about to enter. Click the "Continue" button to proceed.

To return to ENBREL.com, click "Cancel" or close this window.

Privacy Policy  Terms of Use
This site is intended for US Audiences only.
©2013 Amgen, Inc., Thousand Oaks, CA 91320
E-mail this page to a colleague
Please correct the fields marked in red
This content is for US health care professionals only. Amgen will not use your e-mail address or your colleague's e-mail address for any other purpose. To learn more about our use of your information and your rights, please consult our Privacy Policy.

Send another e-mail
Return to enbrel.com/RheumPro


The following information is intended for use only by residents of the United States. Countries outside of the United States may have regulatory requirements or medical practices that are different than those in the United States and may require reference to different or additional information. Therefore, this information may not be appropriate outside of the United States.

If you are a resident of the United States or one of its territories, or a health care professional practicing your profession in the United States or one of its territories, please click below.

If you are a resident of a country other than the United States, please visit the Amgen website to find information about our offices around the globe.
Phil Mickelson: A PsA patient's perspective
Disease activity vs. structural progression in RA
Treating Moderately Active RA
Rapid, Sustained Efficacy of ENBREL
Improving Outcomes in Psoriatic Arthritis
A look back at 15 years